Despite Imfinzi, US accelerated approvals surge

[cafead]

via Monday’s US withdrawal of Astrazeneca’s Imfinzi in urothelial bladder cancer was a long time coming. Imfinzi was among five anti-PD-(L)1 drugs approved for this cancer, going back nearly five years, and despite the failures of several subsequent studies the most the FDA had done was to seek to narrow the scope of some US labels.

article source